Results 131 to 140 of about 33,975 (227)

Polycystic kidney disease

Kidney International, 1982
openaire   +2 more sources

The impact of breast milk relaxin 2, oxytocin, and insulin‐like peptide 3 on neonatal growth parameters in early life

Journal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 6, Page 1479-1487, June 2026.
Abstract Objectives This study aims to quantify the levels of relaxin 2 (RLX2), oxytocin (OXT), and insulin‐like peptide 3 (INSL3) in colostrum (postpartum days 1–5, Visit 1) and mature breast milk (postpartum days 21–35, Visit 2), and to evaluate their associations with neonatal growth outcomes.
Hakan Doneray, Ayse Ozden, Guzide Tavlas, Halil Ibrahim Ozkan   +3 more
wiley   +1 more source

Metformin as a Multifaceted Therapeutic Agent for Gastrointestinal Diseases: Mechanisms, Clinical Efficacy, and Future Directions

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT The high prevalence of gastrointestinal (GI) diseases and their significant impact on the quality of life require new therapeutic strategies. The development of novel therapeutic strategies should prioritize targeting the fundamental pathophysiological mechanisms underlying these diseases, including inflammation, cellular proliferation, and ...
Sayedeh Azimeh Hosseini, Hassan Valadbeigi, Seyedeh Mahdieh Khoshnazar, Saeed Khoshnood, Shahab Falahi, Delsuz Rezaee, Ali Hematian, Mohammad Hossein Haddadi   +7 more
wiley   +1 more source

Protein Tyrosine Phosphatase 1B‐Mediated Granulosa Cell Insulin Resistance Links Metabolic Stress to Aging‐Relevant Ovarian Dysfunction and Is Reversed by Gengnianchun

Aging Cell, Volume 25, Issue 6, June 2026.
Metabolic stress induces insulin resistance and upregulates PTP1B in granulosa cells, leading to aging‐relevant ovarian dysfunction. Gengnianchun (GNC) suppresses PTP1B, restores IRS1–AKT2–GLUT4 signaling, and preserves follicles, highlighting PTP1B as a therapeutic target for ovarian dysfunction in metabolically vulnerable states.
Yanqiu Rao, Ting Xu, Yan Ding, Jun Li, Lingyun Gao, Yun Wang, Wenjun Wang   +6 more
wiley   +1 more source

Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report

Clinical Transplantation, Volume 40, Issue 6, June 2026.
ABSTRACT Introduction The effects of induction therapy with the anti‐CD52 monoclonal antibody alemtuzumab on age‐specific outcomes following kidney transplantation (KT) remain inadequately studied. This study aimed to analyze the comparative safety and efficacy of single‐dose alemtuzumab induction in deceased donor (DD) KT recipients according to ...
Alex Ng, David I. Harriman, Alan C. Farney, Giuseppe Orlando, Colleen Jay, Amber Reeves‐Daniel, Robert J. Stratta   +6 more
wiley   +1 more source

Reduction in Donor‐Derived Cell‐Free DNA After Rejection Treatment is Associated With Improved Long Term Allograft Function

Clinical Transplantation, Volume 40, Issue 6, June 2026.
ABSTRACT Donor derived cell‐free DNA (dd‐cfDNA) has become a useful biomarker for monitoring of kidney transplant rejection, however utilization after rejection is not well established. We conducted a retrospective cohort study of 64 kidney transplant recipients (KTRs) with biopsy‐proven rejection and concomitant dd‐cfDNA monitoring.
Lauren Schumacher, Olivia Philippart, Jesica Yau, Fawad Shuaib, Sravanthi Paluri, Ana Lia Castellanos, Aric Schadler, Hasan Fattah   +7 more
wiley   +1 more source

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical ASCVD Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4975-4990, June 2026.
ABSTRACT Aims To evaluate the association between semaglutide 2.4 mg and major adverse cardiovascular events (MACE) among adults with clinical atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity without diabetes in real‐world clinical practice.
Michael G. Nanna, Carlos Mena‐Hurtado, Victoria Divino, Zhenxiang Zhao, Yan Chen, Joanna Boland, Jinlin Song, Andrea Traina, Kerem Ozer, Filip K. Knop, Kim G. Smolderen   +10 more
wiley   +1 more source

Evidence‐Based Clinical Practice Guidelines for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) 2026

Hepatology Research, Volume 56, Issue 6, Page 887-902, June 2026.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, with an increasing number of patients progressing to cirrhosis and hepatocellular carcinoma (HCC). Early identification of individuals at high risk for advanced fibrosis is essential for preventing liver‐related ...
Norio Akuta, Tomomi Kogiso, Kenichi Ikejima, Motoyuki Otsuka, Takumi Kawaguchi, Miwa Kawanaka, Hirokazu Takahashi, Nobuharu Tamaki, Hayato Nakagawa, Hayato Hikita, Hideki Fujii, Kanji Yamaguchi, Masato Yoneda, Kazuyoshi Kon, Akira Uchiyama, Yuya Seko, Sadatsugu Sakane, Ryuta Shigefuku, Naoto Fujiwara, Michihiro Iwaki, Takashi Kobayashi, Takuya Adachi, Yasuto Takeuchi, Tsubasa Tsutsumi, Dan Nakano, Kaoru Shibayama, Noriyo Urata, Hisamitsu Miyaaki, Hidekatsu Kuroda, Masahiro Koseki, Hirohito Sone, Yasuhiro Matsubayashi, Keisuke Kakisaka, Atsushi Takai, Kazuo Notsumata, Masataka Seike, Yoshiyuki Takei, Yoshifumi Takeyama, Susumu Eguchi, Sumio Watanabe, Hajime Isomoto, Hiroshi Yotsuyanagi, Takao Itoi, Tetsuo Takehara, Satoshi Mochida   +44 more
wiley   +1 more source

Practical recommendations for treating patients with chronic kidney disease in Australia: a multidisciplinary approach

Internal Medicine Journal, Volume 56, Issue 6, Page 966-975, June 2026.
Abstract Background Chronic kidney disease (CKD) is a significant public health challenge in Australia, affecting ~10% of the adult population and contributing to substantial morbidity and mortality. Diabetes, hypertension, cardiovascular disease and CKD frequently co‐exist; therefore, a multidisciplinary approach is necessary to manage these ...
M. P. Schlaich, W. P. Abhayaratna, R. Audehm, E. I. Ekinci, R. J. MacIsaac, A. J. Nelson, A. Sharma, C. Pollock   +7 more
wiley   +1 more source

Caring for Australians and New ZealandeRs with kidney Impairment guideline commentary on kidney disease: improving global outcomes 2025 guidelines for diagnosis and management of autosomal polycystic kidney disease

Internal Medicine Journal, Volume 56, Issue 6, Page 1068-1073, June 2026.
Abstract Autosomal polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease. The international guideline developer, Kidney Disease: Improving Global Outcomes (KDIGO), published a 2025 clinical practice guideline reflecting advances in genetic testing and the first disease‐modifying agent, tolvaptan.
Mia E. Abdy, Kitty St Pierre, Emily Major, Stephen I. Alexander, Brydee Cashmore, Helen Coolican, Vanessa Cullen, Jessica Dawson, Kelly Lambert, Vincent W. Lee, Amali Mallawaarachi, Gopala Rangan, Judy Savige, Santosh Varughese, David J. Tunnicliffe, Andrew J. Mallett, on behalf of the CARI Guidelines Steering Committee, Emily See, Leanne Brown, Jonathan Craig, Jeffrey Ha, Rathika Krishnasamy, Casey Light, Emmy O'Neill, Thu Nguyen, Hannah Smith, Andrea Viecelli   +26 more
wiley   +1 more source